NGS-Based RNA Sequencing Market Research Report, Analysis and Forecast, till 2030

Transformative Growth Drivers in the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market is undergoing transformative shifts as technological innovations rapidly advance. For instance, the scalability of next-generation sequencing platforms has redefined RNA analysis workflows, allowing researchers to decode transcriptome profiles with exceptional depth and precision. Datavagyanik observes that the rise of personalized medicine and biomarker-driven drug development has strongly accelerated the adoption of NGS-based RNA sequencing across pharmaceutical research, academic laboratories, and clinical diagnostics. As an example, the demand for high-resolution transcriptomic data has increased by more than 20% annually, reflecting an urgency for more robust gene expression profiling tools that traditional techniques cannot match.

Rising Clinical Applications Fueling the NGS-Based RNA Sequencing Market

In clinical diagnostics, the NGS-Based RNA Sequencing Market is driven by its ability to characterize gene fusions, novel transcripts, and splicing variants linked to complex diseases such as cancer. For instance, hematologic malignancies increasingly require molecular-level characterization to optimize treatment regimens, driving widespread adoption of NGS-based methods. According to Datavagyanik, more than 60% of hematology-focused clinical trials now integrate RNA sequencing to identify actionable genetic targets, which is directly influencing market expansion. This growing clinical relevance is expected to contribute to the consistent double-digit growth of the NGS-Based RNA Sequencing Market in the coming years.

Accelerated Research Funding Bolstering the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market is further supported by a steady inflow of funding for genomics research. For instance, governments and private funding agencies in North America and Europe have collectively invested over USD 4 billion in the past five years to advance sequencing technologies, including RNA sequencing. Datavagyanik highlights that these funding initiatives are strengthening research pipelines in oncology, immunology, and neurobiology, boosting the adoption of next-generation transcriptome analysis tools. Such a funding landscape ensures that the NGS-Based RNA Sequencing Market will remain highly resilient to economic fluctuations and research budget cuts.

Technological Advancements Shaping the NGS-Based RNA Sequencing Market

In terms of technology, the NGS-Based RNA Sequencing Market is benefiting from continuous innovations that enhance throughput, read accuracy, and cost efficiency. For example, the introduction of nanopore-based sequencing and long-read platforms has empowered researchers to overcome the limitations of short-read sequencing, enabling full-length isoform detection with greater confidence. Datavagyanik underlines that the transition toward these advanced technologies is accelerating partnerships between instrument manufacturers and service providers, further stimulating growth in the NGS-Based RNA Sequencing Market. Moreover, improvements in library preparation chemistries and automation solutions have reduced turnaround times, supporting the clinical translation of RNA sequencing.

Expanding Precision Medicine Driving the NGS-Based RNA Sequencing Market

The global shift toward precision medicine is another critical driver for the NGS-Based RNA Sequencing Market. For instance, cancer therapeutics now increasingly rely on transcriptome-level biomarkers to guide patient-specific treatment decisions. The market is seeing a surge in demand for RNA-based companion diagnostics, which Datavagyanik identifies as a strategic priority for pharmaceutical companies. As an illustration, companion diagnostics collaborations grew by over 30% in 2024 alone, reflecting confidence in NGS-based platforms as essential pillars of future precision oncology. These trends are directly translating into robust growth for the NGS-Based RNA Sequencing Market.

Rising Adoption in Infectious Disease Research and the NGS-Based RNA Sequencing Market

Beyond oncology, the NGS-Based RNA Sequencing Market is gaining momentum in infectious disease research. For instance, advanced transcriptomic approaches have played a vital role in understanding host-pathogen interactions, especially during outbreaks such as COVID-19 and influenza. Datavagyanik notes that researchers have increasingly prioritized transcriptomic surveillance to monitor viral evolution and host immune responses, strengthening the positioning of NGS-based RNA sequencing solutions. This broadening of application areas has resulted in a compound annual growth rate exceeding 15% for the NGS-Based RNA Sequencing Market within the infectious disease segment.

Cost Efficiency Supporting the NGS-Based RNA Sequencing Market

Cost considerations have historically limited the adoption of advanced sequencing platforms, but the NGS-Based RNA Sequencing Market is witnessing significant price reductions. For example, sequencing costs per megabase have fallen by more than 50% in the last five years, enabling smaller laboratories and emerging biotech startups to leverage RNA sequencing capabilities. Datavagyanik suggests that this democratization of sequencing access is promoting the proliferation of decentralized transcriptomic analysis, which will sustain momentum across the NGS-Based RNA Sequencing Market for the foreseeable future.

Pharmaceutical Collaborations Strengthening the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market has also been strengthened by an expanding network of partnerships between pharmaceutical companies and sequencing technology developers. For instance, large pharmaceutical organizations are investing in RNA sequencing platforms to accelerate biomarker discovery and stratify patient cohorts more effectively. Datavagyanik identifies a nearly 40% rise in strategic alliances between pharma and sequencing providers over the past three years, indicating that collaborative ecosystems are now a fundamental growth pillar for the NGS-Based RNA Sequencing Market. These partnerships not only expand market access but also foster rapid innovation and clinical validation pipelines.

Growing Demand for Single-Cell Sequencing in the NGS-Based RNA Sequencing Market

Single-cell sequencing has emerged as one of the most promising frontiers within the NGS-Based RNA Sequencing Market. For instance, single-cell RNA sequencing is critical for unraveling cellular heterogeneity in complex tissues such as the brain and tumors. Datavagyanik projects that the demand for single-cell transcriptomic solutions will grow at more than 25% annually through 2028, driven by the need to map rare cell populations and understand their role in disease pathogenesis. This surge in single-cell applications is reshaping product development strategies and strengthening the revenue outlook for the NGS-Based RNA Sequencing Market.

Regional Expansion and the NGS-Based RNA Sequencing Market

Regional expansion remains a powerful trend influencing the NGS-Based RNA Sequencing Market. For example, Asia-Pacific has witnessed rapid growth, supported by increasing government investments in precision health initiatives and genomics infrastructure. Datavagyanik highlights that countries such as China, Japan, and South Korea are developing ambitious national genome sequencing programs, which directly fuel demand for advanced RNA sequencing solutions. The Asia-Pacific segment is projected to achieve a compound annual growth rate above 18% over the next five years, making it a highly attractive opportunity area within the global NGS-Based RNA Sequencing Market.

NGS-Based RNA Sequencing Market Size and Growth Outlook

Datavagyanik estimates that the NGS-Based RNA Sequencing Market Size surpassed USD 2 billion in 2024, supported by its growing relevance across research, clinical, and biopharmaceutical sectors. For instance, transcriptomic workflows have become essential to translational research pipelines, which has expanded the addressable customer base for sequencing service providers and reagent manufacturers alike. With growth expected to continue at a double-digit pace, the NGS-Based RNA Sequencing Market Size is forecast to cross USD 4.5 billion by 2029, reflecting consistent innovation and expanding end-user adoption globally.

Regulatory Advancements Impacting the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market is also benefiting from progressive regulatory frameworks that streamline approvals for molecular diagnostics. For instance, regulatory agencies have developed clearer guidelines for clinical-grade sequencing tests, reducing barriers to commercialization. Datavagyanik notes that regulatory harmonization across regions has facilitated cross-border collaboration and faster validation of NGS-based RNA sequencing assays. These advances are expected to encourage broader clinical implementation, further solidifying the NGS-Based RNA Sequencing Market as an indispensable part of modern precision health.

Evolving Data Analysis Solutions Enabling the NGS-Based RNA Sequencing Market

Finally, robust bioinformatics tools are strengthening the competitiveness of the NGS-Based RNA Sequencing Market. For example, scalable cloud-based pipelines now allow researchers to process and analyze massive transcriptomic datasets in near real time. Datavagyanik reports that bioinformatics innovation has reduced analysis turnaround times by more than 40%, eliminating bottlenecks that once delayed RNA sequencing projects. These capabilities are crucial as research complexity grows, supporting a reliable, scalable ecosystem for the NGS-Based RNA Sequencing Market.

Outlook for the NGS-Based RNA Sequencing Market

Looking ahead, Datavagyanik sees the NGS-Based RNA Sequencing Market positioned for sustained expansion as precision medicine, infectious disease surveillance, and translational research all continue to drive demand. For instance, emerging frontiers such as spatial transcriptomics and multi-omics are already influencing development priorities, ensuring that RNA sequencing will remain a cornerstone of biological discovery. These advances will further strengthen global interest, keeping the NGS-Based RNA Sequencing Market on a robust growth trajectory.

Geographical Expansion and the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market is experiencing dynamic geographical expansion as nations race to integrate high-throughput sequencing into their healthcare and research ecosystems. For instance, North America remains a commanding hub for advanced transcriptomic technologies, with the United States accounting for nearly 45% of the global NGS-Based RNA Sequencing Market. Datavagyanik highlights that federal funding programs in the United States, such as precision medicine initiatives, continue to drive large-scale sequencing projects, boosting regional NGS-Based RNA Sequencing demand. Additionally, Canada’s growing investment in academic and translational genomics platforms has resulted in a consistent 12% year-over-year increase in regional market share.

Europe’s Emerging Leadership in the NGS-Based RNA Sequencing Market

Europe has emerged as a powerful growth driver for the NGS-Based RNA Sequencing Market. For example, the region’s emphasis on personalized healthcare solutions and genomic medicine strategies is creating robust opportunities. Datavagyanik reports that the European Union allocated over USD 1 billion in recent funding rounds to strengthen molecular diagnostics research, which is directly elevating NGS-Based RNA Sequencing demand across major economies such as Germany, France, and the UK. These countries have also been early adopters of companion diagnostics pipelines, with more than 500 clinical laboratories integrating next-generation transcriptomic analysis since 2022. Such investments are fostering an optimistic growth trajectory in the European NGS-Based RNA Sequencing Market.

Asia-Pacific Driving Next-Gen Growth in the NGS-Based RNA Sequencing Market

In Asia-Pacific, the NGS-Based RNA Sequencing Market is expanding at one of the highest global growth rates. For instance, China has launched multiple government-funded genome sequencing initiatives, aiming to sequence millions of citizens over the next five years. Datavagyanik identifies that these programs are creating massive new NGS-Based RNA Sequencing demand, with Chinese academic and hospital networks investing aggressively in high-throughput sequencing platforms. Japan is also prioritizing RNA sequencing to support regenerative medicine and rare disease research, while South Korea’s expanding genomics R&D infrastructure is projected to drive regional NGS-Based RNA Sequencing Market growth by more than 20% annually through 2030. The Asia-Pacific region is well positioned to be a global powerhouse in advanced transcriptomic technologies.

Latin America and the NGS-Based RNA Sequencing Market

Latin America is gradually emerging as a promising player in the NGS-Based RNA Sequencing Market. For instance, Brazil and Mexico have initiated national precision medicine programs that incorporate RNA sequencing to better characterize population health profiles. Datavagyanik emphasizes that partnerships between Latin American universities and global pharmaceutical organizations are strengthening knowledge transfer and technological adoption, supporting a 10% compound annual growth rate for NGS-Based RNA Sequencing demand in the region. Although infrastructure challenges persist, rising healthcare expenditure and research collaborations are likely to accelerate NGS-Based RNA Sequencing Market penetration in Latin America over the next decade.

Middle East and Africa’s Contribution to the NGS-Based RNA Sequencing Market

The Middle East and Africa represent an emerging frontier for the NGS-Based RNA Sequencing Market. For example, Gulf countries are prioritizing advanced genomic initiatives to diversify their healthcare economies, with Saudi Arabia and the UAE investing in state-of-the-art sequencing laboratories. Datavagyanik projects a significant uplift in NGS-Based RNA Sequencing demand from regional centers of excellence that focus on hereditary disease mapping and rare disease discovery. Although adoption rates are currently lower compared to Europe or North America, Datavagyanik anticipates annual growth exceeding 15% as knowledge transfer programs and local manufacturing capabilities continue to mature.

Market Segmentation Transforming the NGS-Based RNA Sequencing Market

Segmentation within the NGS-Based RNA Sequencing Market is evolving to address a growing diversity of application needs. For instance, whole-transcriptome sequencing remains the dominant segment, capturing more than 60% of market revenues as researchers demand comprehensive gene expression profiling. Datavagyanik notes that targeted RNA sequencing is growing at a faster pace, with an annual expansion of over 18% due to its cost-effective focus on key biomarker panels. Single-cell RNA sequencing is also emerging as a high-growth segment, expanding the NGS-Based RNA Sequencing Market footprint in immunology, neurodegeneration, and oncology. By 2030, it is expected that single-cell technologies will command nearly a quarter of global market share, driven by a need to decode cellular heterogeneity with unprecedented accuracy.

Platform Segmentation in the NGS-Based RNA Sequencing Market

Platform-based segmentation continues to shape the NGS-Based RNA Sequencing Market. For example, Illumina platforms maintain strong leadership, capturing more than 50% of the installed base due to their reliability and broad reagent ecosystems. Datavagyanik underscores that emerging long-read sequencing platforms, such as those built on nanopore and SMRT technologies, are gaining traction with a growth rate of over 22% per year as researchers seek to overcome the read-length limitations of short-read technologies. This diversity of sequencing platforms enables end-users to tailor transcriptomic projects to their analytical requirements, strengthening competitive differentiation in the NGS-Based RNA Sequencing Market.

End-User Segmentation in the NGS-Based RNA Sequencing Market

The end-user landscape of the NGS-Based RNA Sequencing Market is increasingly fragmented. For instance, academic and research institutes continue to be the largest contributors, accounting for nearly 45% of the global market revenue. Datavagyanik highlights that pharmaceutical and biotechnology companies are rapidly expanding their share, supported by biomarker-driven drug discovery pipelines and advanced companion diagnostics. Hospital laboratories are also adopting RNA sequencing for clinical-grade testing, resulting in an annual growth rate of more than 16% within this segment. Such diversification is reinforcing the resilience of the NGS-Based RNA Sequencing Market, ensuring that growth is not reliant on a single vertical.

Price Trends Influencing the NGS-Based RNA Sequencing Market

The pricing landscape of the NGS-Based RNA Sequencing Market is transforming, making advanced transcriptomic analysis more accessible. For example, Datavagyanik notes that sequencing costs per sample have declined by almost 40% since 2020, largely due to innovations in reagents, library prep automation, and streamlined data analysis pipelines. For smaller laboratories and emerging markets, this price reduction has been crucial in fostering NGS-Based RNA Sequencing demand. Furthermore, increasing competition among platform providers is fueling price-based differentiation strategies, giving end-users more choices without compromising data quality. As sequencing technologies become even more efficient, Datavagyanik projects additional price compression of around 15% by 2027, helping to democratize the NGS-Based RNA Sequencing Market further.

Regional Price Variation in the NGS-Based RNA Sequencing Market

Price trends within the NGS-Based RNA Sequencing Market also display regional variations. For instance, North America maintains premium pricing levels due to advanced regulatory requirements and demand for high-complexity testing, while Asia-Pacific is experiencing greater price competitiveness as local players scale up sequencing reagent manufacturing. Datavagyanik observes that Europe is gradually aligning prices with North American standards, reflecting harmonized regulatory frameworks and rigorous quality expectations. These shifts are creating a more level playing field globally and promoting consistent growth in NGS-Based RNA Sequencing demand across all regions.

Impact of Workflow Automation on the NGS-Based RNA Sequencing Market Pricing

Workflow automation has become a decisive factor in shaping pricing trends in the NGS-Based RNA Sequencing Market. For example, fully integrated automation systems can cut labor costs by more than 35%, providing laboratories with the opportunity to pass savings on to clients while maintaining robust margins. Datavagyanik emphasizes that the transition to automated workflows is accelerating adoption in mid-tier and small-scale facilities, which historically faced resource bottlenecks. This new price-access model is expected to contribute to the long-term sustainability of the NGS-Based RNA Sequencing Market, broadening its reach to underfunded research and clinical segments.

Rising Data Storage Needs and Their Influence on the NGS-Based RNA Sequencing Market

As sequencing depth grows, the NGS-Based RNA Sequencing Market must also address escalating data storage and management costs. For example, high-throughput RNA sequencing experiments can generate terabytes of data, creating significant storage burdens. Datavagyanik reports that cloud-based solutions are increasingly adopted to offset these infrastructure challenges, reducing on-premise hardware costs by up to 50%. This migration to scalable data environments supports steady NGS-Based RNA Sequencing demand by simplifying IT complexity for research labs and clinical facilities. The synergy between sequencing hardware providers and bioinformatics companies is likely to drive further cost efficiencies and keep pricing attractive.

Technological Convergence Reshaping the NGS-Based RNA Sequencing Market Segmentation

The convergence of sequencing with other high-throughput methods is also transforming the NGS-Based RNA Sequencing Market. For example, spatial transcriptomics is now complementing traditional RNA sequencing by adding tissue context to gene expression profiles. Datavagyanik indicates that this hybrid segment is growing at over 28% annually, creating a new branch of the NGS-Based RNA Sequencing Market that targets advanced oncology research and immunotherapy. These integrated applications will expand segmentation options for vendors while responding to growing customer expectations for multi-dimensional datasets, ensuring long-term market resilience.

Competitive Pricing Strategies Within the NGS-Based RNA Sequencing Market

Competitive pricing strategies are now core to sustaining growth in the NGS-Based RNA Sequencing Market. For instance, market leaders are adopting bundled pricing models, including instrument rental, reagent packages, and data analysis services under one contract. Datavagyanik points out that this approach has proven highly effective in increasing NGS-Based RNA Sequencing demand among smaller biopharma companies with limited upfront budgets. These subscription-based offerings are projected to rise by over 20% annually through 2029, strengthening recurring revenue and lowering barriers to adoption for emerging players.

NGS-Based RNA Sequencing Market Future Outlook in Segmentation and Pricing

Looking forward, Datavagyanik expects the segmentation and pricing structure of the NGS-Based RNA Sequencing Market to evolve dynamically, supporting broader application use cases. For example, multi-omics integration, minimal sample input techniques, and liquid biopsy applications will diversify the customer base even further, reinforcing global NGS-Based RNA Sequencing demand. These technological and operational breakthroughs will help keep price points competitive while expanding analytical capabilities, ultimately driving the market toward robust, inclusive, and sustainable growth patterns.

Regional Partnerships Driving NGS-Based RNA Sequencing Market Development

Regional partnerships will continue to shape the evolution of the NGS-Based RNA Sequencing Market. For example, public-private partnerships in Europe and Asia are reducing time-to-market for innovative sequencing applications, helping local facilities meet rising NGS-Based RNA Sequencing demand. Datavagyanik anticipates that by 2030, nearly 35% of all sequencing projects will involve multi-stakeholder partnerships, accelerating knowledge sharing and promoting cost optimization. This collaborative framework ensures that the NGS-Based RNA Sequencing Market remains adaptive and prepared to support next-generation scientific breakthroughs.

Consolidation Trends Impacting the NGS-Based RNA Sequencing Market

Finally, consolidation trends are likely to influence the competitive environment of the NGS-Based RNA Sequencing Market. For instance, mergers between sequencing reagent suppliers and data analysis firms are already reshaping cost structures and distribution models. Datavagyanik emphasizes that vertical integration is helping companies manage pricing pressures more effectively while delivering a seamless customer experience. These consolidation moves are expected to intensify, improving efficiency and supporting robust NGS-Based RNA Sequencing demand in a highly competitive ecosystem.

Key Players and Their Influence on the NGS-Based RNA Sequencing Market

The NGS-Based RNA Sequencing Market is shaped by a competitive array of companies that drive innovation, technological advancements, and strategic growth. These industry leaders collectively account for a significant share of the global market, influencing trends and standards across research, diagnostics, and precision medicine.

Illumina – Market Leader in RNA Sequencing Platforms

Illumina holds a dominant position in the NGS-Based RNA Sequencing Market, commanding approximately 50–55% market share. Its flagship product, the NovaSeq 6000, delivers ultra-high throughput transcriptome data and scales from whole-transcriptome analysis to single-cell applications. For example, the NovaSeq Flow Cell S4 allows up to 20 billion reads per run, enabling large cohort studies and clinical trials. Illumina’s NextSeq and MiSeq platforms also fill critical mid- and low-throughput niches, reinforcing its end-to-end market coverage.

Thermo Fisher Scientific – Broad Offerings in Targeted RNA Sequencing

Thermo Fisher Scientific secures around 15–18% of the NGS-Based RNA Sequencing Market. Its Ion Torrent Genexus System and Ion GeneStudio S5 serve as powerful solutions for targeted RNA panels, offering rapid turnaround times that meet clinical and translational research needs. The company’s Ion AmpliSeq Transcriptome Human Gene Expression Core Panel allows users to quantify over 20,000 human genes with a minimal input requirement, making it attractive for applications where sample input is constrained.

Pacific Biosciences – Stronghold in Long-Read Transcriptomics

Pacific Biosciences, with approximately 8–10% share of the NGS-Based RNA Sequencing Market, specializes in long-read RNA sequencing. Its Sequel IIe system supports full-length cDNA sequencing for isoform detection and splice variant analysis, addressing areas that short-read systems cannot easily resolve. The HiFi read accuracy of 99.9% makes it especially valuable for complex transcriptome characterization in oncology and neurological disease research.

Oxford Nanopore Technologies – Emerging Disruptor

Oxford Nanopore Technologies has quickly emerged as a disruptive force, capturing around 5–7% of the NGS-Based RNA Sequencing Market. Its PromethION and MinION platforms offer direct RNA sequencing without amplification, preserving nucleotide modifications and enabling real-time, portable transcriptome profiling. For instance, the MinION device has been widely applied in field-based infectious disease surveillance, contributing to a growing base of RNA sequencing demand outside laboratory settings.

BGI – High-Throughput Sequencing Powerhouse

BGI retains 8–10% of the NGS-Based RNA Sequencing Market with its MGISEQ-2000 and DNBSEQ-T7 Series. These platforms offer competitive throughput and cost advantages relative to established players, driving RNA sequencing demand in Asia-Pacific and emerging markets. Their high-density patterned arrays reduce duplication rates and optimize data yield, making them a strong choice for large-scale population and agricultural transcriptomics.

QIAGEN – Leader in Sample Prep and Bioinformatics

QIAGEN commands around 3–5% of the NGS-Based RNA Sequencing Market through integrated sample preparation, library construction, and analysis solutions. Products such as the QIAseq FX RNA Library Kit streamline workflows from RNA extraction to data interpretation. QIAGEN’s CLC Genomics Workbench provides user-friendly transcriptome analysis pipelines, supporting labs with minimal bioinformatics capabilities.

Agilent Technologies – Specialized Automation and Reagents

Agilent holds 2–4% share, focusing on targeted RNA sequencing and automation. The Bravo Automated Liquid Handling Platform enables scalable sample prep workflows, while the SureSelect Strand-Specific RNA Library Preparation Kit supports advanced transcriptome capture assays. These tools cater to labs requiring high precision and reproducibility in RNA library generation.

Roche Sequencing Solutions – Expanding Transcriptome Capabilities

Roche, with a growing share of 2–3%, offers innovative RNA sequencing services through its AVENIO Targeted RNA Panels. Although newer to the NGS-Based RNA Sequencing Market, Roche focuses on translational and clinical research, especially in oncology. The AVENIO panels allow simultaneous detection of gene fusions, splice variants, and expression levels in a user-friendly workflow.

Others – Regional and Specialty Players

Several niche and regional vendors contribute the remainder of the market. Companies such as Lexogen (STRM RNA Library Prep Kits), Bio-Rad (ddPCR workflows integrated with RNA sequencing), and Takara Bio (SMART-Seq Kits) collectively fulfill specialized demands in single-cell and low-input RNA sequencing arenas. These players often lead in emerging or highly focused segments.

Comparative Market Share Summary

Company	Market Share Range	Key Products/Services
Illumina	50–55%	NovaSeq 6000, NextSeq, MiSeq
Thermo Fisher Scientific	15–18%	Ion Torrent Genexus, Ion GeneStudio S5, Ion AmpliSeq Transcriptome Panels
Pacific Biosciences	8–10%	Sequel IIe with HiFi reads
Oxford Nanopore Technologies	5–7%	PromethION, MinION (direct RNA sequencing)
BGI	8–10%	MGISEQ-2000, DNBSEQ-T7 Series
QIAGEN	3–5%	QIAseq FX RNA Library Kit, CLC Genomics Workbench
Agilent Technologies	2–4%	Bravo Liquid Handling Platform, SureSelect RNA Prep Kits
Roche Sequencing Solutions	2–3%	AVENIO Targeted RNA Panels
Other niche/regional players	Remainder	Lexogen, Bio-Rad, Takara Bio, and others

Recent Industry Developments in the NGS-Based RNA Sequencing Market

March 5, 2025 – Illumina launches a new reagent kit for the NovaSeq 6000, reducing per-sample cost by 20% and enabling smaller labs to participate in large transcriptome studies.
• January 20, 2025 – Thermo Fisher unveils an improved Ion GeneStudio S5 Prime system with faster runtime, enabling RNA-seq applications to be executed within hours for clinical testing.
• February 15, 2025 – Oxford Nanopore announces validation of direct RNA sequencing on the PromethION for methylation analysis, expanding NGS-Based RNA Sequencing Market opportunities in epitranscriptomics.
• April 10, 2025 – BGI opens its third regional sequencing center in Southeast Asia, equipped with DNBSEQ-T7 platforms, supporting rising demand in population-scale genomics and transcriptomics.
• May 28, 2025 – QIAGEN introduces an automated RNA library prep and analysis workflow with CLC Genomics Workbench that reduces hands-on time by half, accelerating throughput for mid-scale laboratories.
• June 18, 2025 – Roche secures FDA breakthrough designation for its AVENIO Fusion RNA Panel aimed at detecting rare fusion transcripts in solid tumors, marking a key milestone in clinical NGS-Based RNA Sequencing Market expansion.

These developments underscore how leading players are advancing products, expanding geographic access, and attaining regulatory milestones—all of which are fueling the overall momentum of the NGS-Based RNA Sequencing Market.

Key Insights that the NGS-Based RNA Sequencing Market analysis report presents are:

NGS-Based RNA Sequencing Market revenue and demand by countries
Break-down of the NGS-Based RNA Sequencing Market in terms of application areas, target customers, and other potential market segments
Areas that are relatively more potential and are faster growing
NGS-Based RNA Sequencing Market competitive scenario, market share analysis
NGS-Based RNA Sequencing Market business opportunity analysis

Global and Country-Wise NGS-Based RNA Sequencing Market Statistics

Global and Country-Wise NGS-Based RNA Sequencing Market Size ($Million) and Forecast, till 2030
Global and Country-Wise NGS-Based RNA Sequencing Market Trend Analysis
Global and Country-Wise NGS-Based RNA Sequencing Market Business Opportunity Assessment